

Jun Qian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3664455/publications.pdf>

Version: 2024-02-01

61
papers

1,694
citations

304743

22
h-index

302126

39
g-index

63
all docs

63
docs citations

63
times ranked

1989
citing authors

#	ARTICLE	IF	CITATIONS
1	Biologically Inspired Polydopamine Capped Gold Nanorods for Drug Delivery and Light-Mediated Cancer Therapy. ACS Applied Materials & Interfaces, 2016, 8, 24368-24384.	8.0	162
2	Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. PLoS ONE, 2011, 6, e26906.	2.5	110
3	The M2 macrophage marker <i>CD206</i> : a novel prognostic indicator for acute myeloid leukemia. OncoImmunology, 2020, 9, 1683347.	4.6	102
4	IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Annals of Hematology, 2012, 91, 519-525.	1.8	96
5	H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia. Clinical Epigenetics, 2018, 10, 47.	4.1	79
6	U2AF1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. PLoS ONE, 2012, 7, e45760.	2.5	75
7	RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia. Clinical Biochemistry, 2013, 46, 579-583.	1.9	60
8	Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Oncotarget, 2017, 8, 41498-41507.	1.8	58
9	Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leukemia Research, 2013, 37, 1642-1647.	0.8	57
10	Aggregation-Induced Emission (AIE) Nanoparticles-Assisted NIR Fluorescence Imaging-Guided Diagnosis and Surgery for Inflammatory Bowel Disease (IBD). Advanced Healthcare Materials, 2021, 10, e2101043.	7.6	50
11	Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia. Leukemia Research, 2013, 37, 765-768.	0.8	49
12	Epigenetic dysregulation of <i>ID4</i> predicts disease progression and treatment outcome in myeloid malignancies. Journal of Cellular and Molecular Medicine, 2017, 21, 1468-1481.	3.6	43
13	MiR-378 Promotes the Migration of Liver Cancer Cells by Down-Regulating Fus Expression. Cellular Physiology and Biochemistry, 2014, 34, 2266-2274.	1.6	42
14	Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. International Journal of Clinical and Experimental Pathology, 2014, 7, 6832-40.	0.5	41
15	A historical review of aggregation-induced emission from 2001 to 2020: A bibliometric analysis. Aggregate, 2022, 3, .	9.9	37
16	CEBPA methylation and mutation in myelodysplastic syndrome. Medical Oncology, 2015, 32, 192.	2.5	31
17	Reduced <i>miR-215</i> expression predicts poor prognosis in patients with acute myeloid leukemia. Japanese Journal of Clinical Oncology, 2016, 46, 350-356.	1.3	29
18	Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies. Clinical Epigenetics, 2018, 10, 92.	4.1	27

#	ARTICLE	IF	CITATIONS
19	Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3295-3304.	2.0	27
20	Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia. <i>Cancer Management and Research</i> , 2018, Volume 10, 4999-5007.	1.9	26
21	Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia. <i>Medical Oncology</i> , 2015, 32, 386.	2.5	25
22	Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 2444-2450.	4.1	25
23	Detection of SRSF2-P95 Mutation by High-Resolution Melting Curve Analysis and Its Effect on Prognosis in Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2014, 9, e115693.	2.5	25
24	TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 5838-5846.	4.1	23
25	The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 10107-10114.	1.8	20
26	CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 123-131.	2.3	20
27	Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 9584-9593.	4.1	19
28	Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2011, 154, 153-155.	2.5	18
29	Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemia. <i>Molecular Carcinogenesis</i> , 2018, 57, 735-744.	2.7	18
30	High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia. <i>Gene</i> , 2018, 640, 79-85.	2.2	18
31	Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2019, 17, 102.	4.4	18
32	MicroRNA-335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia. <i>Aging</i> , 2019, 11, 3376-3391.	3.1	18
33	Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. <i>Clinical Biochemistry</i> , 2011, 44, 779-783.	1.9	17
34	Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 1250-1256.	2.1	17
35	Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 3274-3281.	4.1	17
36	DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 8951-8960.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 6604-6614.	4.1	15
38	Pseudogene <i>BMI1P1</i> expression as a novel predictor for acute myeloid leukemia development and prognosis. <i>Oncotarget</i> , 2016, 7, 47376-47386.	1.8	13
39	Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH ₂ Through Ultrasound to Enhance the Antitumor Efficacy and Attenuate the Toxicity for Treatment of Malignant Glioma. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 6905-6922.	6.7	13
40	Establishment and molecular characterization of decitabine-resistant K562 cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3317-3324.	3.6	12
41	Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1853-1864.	2.5	11
42	A Small Molecule Diketopyrrolopyrrole-Based Dye for in vivo NIR-IIa Fluorescence Bioimaging. <i>Chemistry - A European Journal</i> , 2021, 27, 14240-14249.	3.3	11
43	Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0165948.	2.5	10
44	Development of a High-Resolution Melting Analysis for the Detection of the <i>SF3B1</i> Mutations. <i>Genetic Testing and Molecular Biomarkers</i> , 2013, 17, 342-347.	0.7	9
45	Epigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia. <i>Journal of Cancer</i> , 2017, 8, 460-468.	2.5	9
46	Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia. <i>Tumor Biology</i> , 2017, 39, 101042831769912.	1.8	8
47	Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2018, 16, 135.	4.4	8
48	Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2019, 234, 9438-9446.	4.1	8
49	Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine. <i>Cancer Cell International</i> , 2019, 19, 177.	4.1	7
50	Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5336-44.	0.5	7
51	Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 4707-4714.	4.1	6
52	DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia. <i>Cancer Medicine</i> , 2019, 8, 6393-6402.	2.8	5
53	Expression characteristic of <i>Ig B7-H3</i> and <i>Ig B7-H3</i> in acute myeloid leukemia. <i>Bioengineered</i> , 2021, 12, 11987-12002.	3.2	5
54	Pan-cancer analysis identifies <i>CD300</i> molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia. <i>Cancer Medicine</i> , 2023, 12, 789-807.	2.8	5

#	ARTICLE	IF	CITATIONS
55	Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. <i>Pathology Research and Practice</i> , 2018, 214, 896-901.	2.3	4
56	Abnormal expression and methylation of PRR34 and CAS1 are associated with adverse outcomes in acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 5283-5296.	2.8	4
57	The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4321-31.	0.5	4
58	SOX7 methylation is an independent prognostic factor in myelodysplastic syndromes. <i>Pathology Research and Practice</i> , 2019, 215, 322-328.	2.3	2
59	Hypomethylation of MIR-378 5' flanking region predicts poor survival in young patients with myelodysplastic syndrome. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1067.	1.2	2
60	Reduced expression of lncRNA <i>DLEU7-AS1</i> is a novel favorable prognostic factor in acute myeloid leukemia. <i>Bioscience Reports</i> , 2022, 42, .	2.4	1
61	Methylation-independent expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 4840-4852.	0.0	0